Overcoming Immunosenescence For Effective Stem Cell Therapies
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
An established treatment for blood cancers involves a stem cell transplant to replace the blood stem cells that are damaged by radiation and chemotherapy. However, treatment success is limited with advancing age due to multiple defects in the immune system. We will use new technologies to investigate how the ageing immune system copes with stem cell transplantation and explore new methods for improving recovery and immunity after HSCT.
Cytokine Responses Within The GI Tract Dictate T Cell Fate And Transplant Outcome
Funder
National Health and Medical Research Council
Funding Amount
$1,479,579.00
Summary
Over 10,000 persons per year in Australia are diagnosed with a blood cancer, accounting for 10% of cancer deaths. Stem cell transplantation remains curative therapy for these diseases but is limited by a process known as graft-versus-host disease (GVHD), responsible for mortality in up to 50% of patients. This project will focus on immune responses within the colon as the critical event initiating lethal GVHD, defining new treatments that will be translated to improve transplant outcomes.
Dendritic Cells In Graft-versus-Host Disease Following Bone Marrow Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$180,859.00
Summary
Bone marrow transplantation (BMT) is the only available curative therapy for many blood cancers such as leukaemia. Graft-versus-host disease (GVHD) occurs after BMT and is a major cause of transplant-related death. GVHD occurs when transplanted donor cells “attack” recipient tissues causing widespread damage. Gaining a more comprehensive understanding of this disease process is critically important for the design of new therapies and improvement of outcomes for transplant recipients.
Kinetics, Mechanism And Engraftment Of In Vitro Generated T Cell Precursors As A Strategy To Enhance Thymic Rejuvenation Following Allogeneic Hematopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$403,324.00
Summary
Immune regeneration - following standard cancer therapies such as chemotherapy and radiation-therapy for hematopoietic (blood) stem cell transplant (HSCT) - is one of the most significant unmet clinical challenges today. This research will focus on using “off the shelf” precursor T cells to improve immune reconstitution following HSCT, thereby significantly reducing the incidence of morbidity and mortality following transplantation.
The Role Of Alloantigen Presentation In Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$508,003.00
Summary
Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which d ....Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which drive GVHD.Read moreRead less
Failure Of Donor Antigen Presentation Promotes IL-17 Dependant Chronic GVHD
Funder
National Health and Medical Research Council
Funding Amount
$585,860.00
Summary
Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which d ....Bone marrow transplantation (BMT) is the most effective treatment for a number of haematological conditions, especially leukemia. Graft versus host disease (GVHD) is a complication of BMT and results in the death of up to 50% of transplant recipients. GVHD occurs when the newly transplanted immune system recognizes the recipient as foreign and mounts and immune reponse against the patients tissues. These studies will focus on identifying and understanding the function of the immune cells which drive GVHD.Read moreRead less
The Role Of Gut Resident Antigen Presenting Cells In Graft-versus-host Disease
Funder
National Health and Medical Research Council
Funding Amount
$409,909.00
Summary
Allogeneic stem cell transplantation (SCT) is curative therapy for most blood cancers, since donor immune cells can eliminate cancers which cannot be eradicated by chemotherapy. However these donor cells can also attack normal cells in a process known as graft-versus-host disease. This research aims to understand how immune responses are induced after SCT to promote cancer eradication, whilst inhibiting GVHD, thus curing more patients of cancer and maintaining a normal quality of life.